The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women | Request PDF
Is Teva doomed after Copaxone's increased competition and Laquinimod's failed Phase III trial? - Pharmaceutical Technology
TREATMENT WITH GLATIRAMER ACETATE DELAYS CONVERSION TO CLINICALLY DEFINITE MULTIPLE SCLEROSIS (CDMS) IN PATIENTS WITH CLINICALLY
Insight into the mechanism of laquinimod action - Journal of the Neurological Sciences
Laquinimod - an overview | ScienceDirect Topics
Letter to investigators involved in the Arpeggio study of Laquinimod …
Teva, Active Biotech Present Positive Findings for RRMS Experimental Therapy Laquinimod
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Teva and Active Biotech Expand Investigational MS Treatment Program
Advances in Oral Drugs for Multiple Sclerosis | Erase MS
Active Biotech Regains Rights Over Laquinimod from Teva Pharmaceutical
Multiple Sclerosis Research: Will Teva and Biogen Come together for the sake of DMF, laquinimod polypill
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Laquinimod for Relapsing-Remitting Multiple Sclerosis
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Teva's Respiratory Drugs Contribute 11% to Specialty Medicines
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study - The Lancet
Laquinimod - Wikipedia
Laquinimod - Wikipedia
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington's Disease Trial
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
